J. Nasu

Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer.

T. Fujita, H. Inoue, T. Tsuji, 1995, Gastroenterology.

Polymorphic expression of decay‐accelerating factor in human colorectal cancer

T. Fujita, Y. Endo, T. Tsuji, 2001, Journal of gastroenterology and hepatology.

Enhanced expression of decay‐accelerating factor and CD59/homologous restriction factor 20 in intestinal metaplasia, gastric adenomas and intestinal‐type gastric carcinomas but not in diffuse‐type carcinomas

T. Fujita, T. Tsuji, M. Mizuno, 2002, Histopathology.

ADVANCES IN THE DEVELOPMENT OF A RELIABLE ASSAY FOR THE MEASUREMENT OF STOOL DECAY-ACCELERATING FACTOR IN THE DETECTION OF COLORECTAL CANCER

T. Fujita, Y. Shiratori, Kazuhide Yamamoto, 2002, Journal of immunoassay & immunochemistry.

Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC)

T. Fujita, T. Inaba, T. Tsuji, 1996, Clinical and experimental immunology.

Epidermal growth factor induces expression of decay-accelerating factor in human colonic cancer cells via the mitogen-activated protein kinase pathway.

T. Fujita, Y. Endo, K. Takeuchi, 2001, The Journal of laboratory and clinical medicine.

The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY)

F. Uno, T. Nagasaka, A. Doi, 2019, BMC Cancer.

The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY)

F. Uno, T. Nagasaka, A. Doi, 2019, BMC Cancer.